CD200 (Protein | Antibody | cDNA Clone | ELISA Kit)

All CD200 reagents are produced in house and quality controlled, including 13 CD200 Antibody, 2 CD200 ELISA, 41 CD200 Gene, 6 CD200 Lysate, 6 CD200 Protein, 2 CD200 qPCR. All CD200 reagents are ready to use.

CD200 Protein (6)

CD200 Antibody (13)

CD200 ELISA Kit & Match Antibody ELISA Pair Set (2)

CD200 cDNA Clone (41)

NM_005944.5
NM_010818.3
NM_031518.2

In cloning vector

In lentiviral vector

XM_001103685.2

CD200 Lysate (6)

More Product Popular With Customers

CD200 Background

CD2 (OX-2) is a cell surface glycoprotein that imparts immune privileges by suppressing alloimmune and autoimmune responses through its receptor, CD2R, expressed primarily on myeloid cells. Signals delivered through the CD2:CD2R axis have been shown to play an important role in the regulation of anti-tumor immunity, and overexpression of CD2 has been reported in a number of malignancies, including CLL, as well as on cancer stem cells. The role of CD2-CD2R signaling in immune regulation of the central nervous system has become a popular field of research in recent years. Many studies have shown that there is a close correlation between CD2-CD2R, microglia activation, and Parkinson's disease (PD). The ability of CD2 to suppress myeloid cell activation is critical for maintaining normal tissue homeostasis but may also enhance the survival of migratory neoplastic cells. CD2 and CD2R associate via their respective N-terminal Ig-like domains. CD2 has been characterized as an important immunoregulatory molecule, increased expression of which can lead to decreased transplant rejection, autoimmunity, and allergic disease. Elevated CD2 expression has been reported to be associated with poor prognosis in a number of human malignancies. In addition, CD2 also plays an important role in prevention of graft rejection, autoimmune diseases and spontaneous abortion.

CD200 References

  • Minas K, et al. (2006) Is the CD200/CD200 receptor interaction more than just a myeloid cell inhibitory signal? Crit Rev Immunol. 26(3): 213-30.
  • Wang XJ, et al. (2007) CD200-CD200R regulation of microglia activation in the pathogenesis of Parkinson's disease. J Neuroimmune Pharmacol. 2(3): 259-64.
  • Wong KK, et al. (2010) The role of CD200 in immunity to B cell lymphoma. J Leukoc Biol. 88(2): 361-72.